Article Impact Level: HIGH Data Quality: STRONG Summary of Nature Communications. https://doi.org/10.1038/s41467-026-79136-x Dr. Thirupura S. Shankar et al.
Points
- University of Utah Health researchers investigated the functional role of adipocyte enhancer binding protein one in driving maladaptive myocardial fibrosis and adverse ventricular remodeling during heart failure progression.
- Fibroblast specific knockout or myocardial knockdown of the target gene in murine heart attack models significantly preserved cardiac function and prevented pathological scarring four weeks after injury.
- Experimental suppression initiated after advanced heart failure had already developed failed to improve cardiac performance indicating that early therapeutic timing following initial reparative healing is essential.
- Ex vivo studies using failing human myocardial tissue cultures demonstrated that reducing protein expression reversed pathological cellular architecture and decreased overall tissue scarring levels.
- Authors concluded that targeting this pathway regulates critical fibrotic genes including MRTFB and RUNX2 offering a promising therapeutic strategy to prevent heart failure progression.
Summary
This translational study evaluated the functional role of adipocyte enhancer binding protein 1 (AEBP1) and its full-length protein, aortic carboxypeptidase-like protein (ACLP), in driving maladaptive myocardial fibrosis and heart failure progression. Published in Nature Communications by University of Utah Health researchers led by first author Thirupura Shankar and senior author Dr. Stavros Drakos, the investigation addressed the absence of targeted anti-fibrotic therapies for ischemic and pressure-overload cardiac injury. Given that persistent cardiac fibroblast activation leads to excessive extracellular matrix deposition and adverse ventricular remodeling, the research sought to determine whether suppressing AEBP1 could prevent fibrosis and preserve myocardial function.
In murine models of myocardial ischemia and pressure overload, fibroblast-specific Aebp1 knockout or myocardial knockdown significantly preserved cardiac function and attenuated pathological remodeling at four weeks post-injury. However, lowering AEBP1 levels after heart failure had already progressed failed to restore cardiac function, indicating a preventative rather than curative window following acute healing. In human myocardial tissue cultures, AEBP1 expression was elevated in advanced heart failure, particularly surrounding injured regions. Overexpression of ACLP in non-failing human myocardium induced pathological remodeling, whereas AEBP1 knockdown in failing human heart tissue promoted structural reverse remodeling and reduced fibrosis. Mechanistically, ACLP orchestrated fibroblast activation by regulating MRTFB, RUNX2, SM22, and COL1A1 gene expression.
The authors conclude that AEBP1 is a critical mediator of maladaptive cardiac fibrosis and adverse remodeling following myocardial injury. By precisely timing AEBP1 inhibition after initial reparative scarring, targeted anti-fibrotic therapies could halt heart failure progression and induce reverse remodeling without compromising structural healing.
Link to the article: https://www.nature.com/articles/s41467-026-79136-x
References
Shankar, T. S., Johnson, E., Hamouche, R., Visker, J. R., Ling, J., Amrute, J., Padilla, L., Srinivasan, H., Calder, D., Polishchuk, G., Lunde, T., Jeong, J., Tekarli, B., Sideris, K., Kyriakoulis, I., Navankasattusas, S., Sachse, F. B., Boudina, S., Selzman, C. H., … Drakos, S. G. (2026). Adipocyte enhancer binding protein 1 (Aebp1) inhibition mediates cardiac reverse remodeling by regulating MRTFB and RUNX2 signaling. Nature Communications. https://doi.org/10.1038/s41467-026-79136-x
